Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703559 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances
A Phase 2 study, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01703559 is a Phase 2 study that has completed, run by Ocuphire Pharma. The registered enrollment target is 60 participants.
The verdict
NCT01703559, a Phase 2 study, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The objectives of this study are: * To evaluate the efficacy of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) in the treatment of night vision complaints, including reduced contrast sensitivity * To evaluate the ocular and systemic safety of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) compared to its vehicle, a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
Interventions
- DRUG Phentolamine Mesylate Ophthalmic Solution 1.0%
- DRUG Phentolamine Mesylate Ophthalmic Solution 0.5%
- OTHER Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-09-09 |
| Est. Completion | 2012-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01703559
The ClinicalTrials.gov registry entry for NCT01703559 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocuphire Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Phentolamine Mesylate Ophthalmic Solution 1.0% is the first listed.
NCT01703559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01703559 about?
NCT01703559 is a clinical study titled "The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances". The objectives of this study are: * To evaluate the efficacy of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) in the treatment of night vision complaints, including reduced contrast sensitivity * To evaluate the ocular and systemic safety of phentolamine mesylate 0.5% and 1.0% oph...
What is the current status of trial NCT01703559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2011-09-09. Estimated completion is 2012-04-30.
What interventions are being tested in trial NCT01703559?
The interventions under investigation include: Phentolamine Mesylate Ophthalmic Solution 1.0% (DRUG), Phentolamine Mesylate Ophthalmic Solution 0.5% (DRUG), Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) (OTHER).
Who is sponsoring clinical trial NCT01703559?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.